858678-06-5Relevant academic research and scientific papers
Design, synthesis and evaluation of MCH receptor 1 antagonists - Part II: Optimization of pyridazines toward reduced phospholipidosis and hERG inhibition
Roth, Gerald J.,Heckel, Armin,Kley, J?rg T.,Lehmann, Thorsten,Müller, Stephan G.,Oost, Thorsten,Rudolf, Klaus,Arndt, Kirsten,Budzinski, Ralph,Lenter, Martin,Lotz, Ralf R.H.,Schindler, Marcus,Thomas, Leo,Stenkamp, Dirk
, p. 3270 - 3274 (2015/07/08)
Abstract Despite recent success there remains a high therapeutic need for the development of drugs targeting diseases associated with the metabolic syndrome. As part of our search for safe and effective MCH-R1 antagonists for the treatment of obesity, a s
3-(4-PIPERIDINE-1YLMETHYL-PHENYL)-PROPION ACID-PHENYLAMIDE-DERIVATIVES AND RELATED COMPOUNDS USED IN THE FORM OF MCH ANTAGONISTS (MELANINE CONCENTRATING HORMONE) FOR TREATING EATING DISORDERS
-
Page/Page column 146, (2008/06/13)
The invention relates to amid compounds of general formula (I), wherein groups and residuals A, B, b, W, X, Y, Z, R1, R2 and R3 have significances given in a claim 1. In addition, said invention relates to drugs containing at least one type of inventive amid. Because of the antagonist activity of an MCH-receptor, the inventive drugs are suitable for treating metabolic disturbances and/or eating disorders, in particular adiposity, bulimia, anorexia, hyperphagia and diabetes.
